# 2026-22883: FDA Offers Emergency Playbook for Testing Tomorrow’s Emerging Pathogens

2026-22883, Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency; Guidance for Industry and Food and Drug Administration Staff; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-10, effective 2026-11-10; PRIA reads it as touching household money (as of 2026-11-11).

- Canonical: https://policyrisk.com/federal-register/2026-22883
- As of: 2026-11-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-22883
- Title: Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency; Guidance for Industry and Food and Drug Administration Staff; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 72541
- Published: 2026-11-10
- Effective: 2026-11-10
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-11

## In one line

FDA Offers Emergency Playbook for Testing Tomorrow’s Emerging Pathogens

## Summary

The FDA just released new guidance to help companies quickly test and validate diagnostic devices for new germs during public health emergencies. This makes it easier and faster to get important tests approved or used under emergency rules, helping protect everyone sooner. If you make or use these tests, this update affects you now and could speed up your work without extra costs.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency." The guidance describes general recommendations for the validation of in vitro diagnostic devices (IVDs) for emerging pathogens during an applicable declaration of public health emergency (PHE). This guidance and the associated template include the recommendations that apply to test data and information submitted in a pre-Emergency Use Authorization (EUA), an EUA request, or to a test offered as described in an applicable enforcement discretion policy.

## Effects PRIA read

- Final guidance for emergency IVD validation: benefit, low. The FDA issued a final guidance titled "Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency," announced November 10, 2026. The guidance provides recommendations for validating in vitro diagnostic devices (IVDs) during a section 564 public…
- Streamlined, flexible validation requirements: benefit, medium. The guidance consolidates and streamlines test validation recommendations across diagnostic test types, adds language emphasizing flexibility at different stages of an outbreak, and clarifies FDA's focus on collecting the most important and "least burdensome" information to submit during a section…
- No new Paperwork Reduction Act collections: benefit, low. FDA states that the guidance "contains no new collection of information" under the Paperwork Reduction Act of 1995 and instead refers to previously approved collections with their OMB control numbers. That means the guidance does not create new OMB-approved information collections for test manufact…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-22883 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/10/2026-22883/validation-of-certain-in-vitro-diagnostic-devices-for-emerging-pathogens-during-a-section-564)
- [2026-22883 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22883.pdf)

## Related
- [Previous: 2026-22882, Biweekly Notice; Applications and Amendments to Facility Operating Licenses and…](https://policyrisk.com/federal-register/2026-22882)
- [Next: 2026-22884, SMR, LLC; Palisades SMR, LLC; Pioneer Units 1 and 2; Receipt of Construction Pe…](https://policyrisk.com/federal-register/2026-22884)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-22883 (as of 2026-11-11).